| Literature DB >> 24807056 |
Stefania Bambini1, Matteo De Chiara1, Alessandro Muzzi1, Marirosa Mora1, Jay Lucidarme2, Carina Brehony3, Ray Borrow2, Vega Masignani1, Maurizio Comanducci1, Martin C J Maiden3, Rino Rappuoli4, Mariagrazia Pizza1, Keith A Jolley3.
Abstract
Neisseria adhesin A (NadA), involved in the adhesion and invasion of Neisseria meningitidis into host tissues, is one of the major components of Bexsero, a novel multicomponent vaccine licensed for protection against meningococcal serogroup B in Europe, Australia, and Canada. NadA has been identified in approximately 30% of clinical isolates and in a much lower proportion of carrier isolates. Three protein variants were originally identified in invasive meningococci and named NadA-1, NadA-2, and NadA-3, whereas most carrier isolates either lacked the gene or harbored a different variant, NadA-4. Further analysis of isolates belonging to the sequence type 213 (ST-213) clonal complex identified NadA-5, which was structurally similar to NadA-4, but more distantly related to NadA-1, -2, and -3. At the time of this writing, more than 89 distinct nadA allele sequences and 43 distinct peptides have been described. Here, we present a revised nomenclature system, taking into account the complete data set, which is compatible with previous classification schemes and is expandable. The main features of this new scheme include (i) the grouping of the previously named NadA-2 and NadA-3 variants into a single NadA-2/3 variant, (ii) the grouping of the previously assigned NadA-4 and NadA-5 variants into a single NadA-4/5 variant, (iii) the introduction of an additional variant (NadA-6), and (iv) the classification of the variants into two main groups, named groups I and II. To facilitate querying of the sequences and submission of new allele sequences, the nucleotide and amino acid sequences are available at http://pubmlst.org/neisseria/NadA/.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24807056 PMCID: PMC4097447 DOI: 10.1128/CVI.00825-13
Source DB: PubMed Journal: Clin Vaccine Immunol ISSN: 1556-679X